A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (NCT04929210)

🧪 Interventions in This Study

• Guselkumab (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (242 Sites)

Showing the first 25 of 242 sites.

• Arizona Arthritis and Rheumatology Research PLLC 1 — Avondale, Arizona
• Arizona Arthritis & Rheumatology Research, PLLC — Chandler, Arizona
• Arizona Arthritis and Rheumatology Research PLLC — Mesa, Arizona
• Arizona Arthritis Research, PLC. — Phoenix, Arizona
• Arizona Arthritis and Rheumatology Associates — Sun City, Arizona
• Southern Arizona VA Healthcare System — Tucson, Arizona
• Unity Health-White County Medical Center — Searcy, Arkansas
• Kaiser Permanent Medical Center — Fontana, California
• Newport Huntington Medical Group — Huntington Beach, California
• University Of California San Diego — La Jolla, California
• Rheumatology Center of San Diego — San Diego, California
• Clinical Research Center of Connecticut — Danbury, Connecticut
• Bay Pines VA Healthcare System — Bay Pines, Florida
• Integral Rheumatology And Immunology Specialists — Plantation, Florida
• Florida Medical Clinic, P.A. — Zephyrhills, Florida
• Great Lakes Clinical Trials — Chicago, Illinois
• OrthoIllinois — Rockford, Illinois
• Willow Rheumatology and Wellness — Willowbrook, Illinois
• Johns Hopkins Bayview Medical — Baltimore, Maryland
• Klein And Associates M D P A — Hagerstown, Maryland
• Clinical Research Institute of Michigan, LLC — Saint Clair Shores, Michigan
• St. Paul Rheumatology P A — Eagan, Minnesota
• Kansas City Physician Partners — Kansas City, Missouri
• Clinvest — Springfield, Missouri
• STAT Research, Inc. — Vandalia, Ohio

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Arthritis, Psoriatic

• A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice — Buenos Aires,
• Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug — Avondale, Arizona
• A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis — Jonesboro, Arkansas
• A Study of Guselkumab in Participants With Active Psoriatic Arthritis — Birmingham, Alabama
• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis — Glendale, Arizona

Explore by condition: All Arthritis, Psoriatic clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.